CN101448854A - 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白 - Google Patents

包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白 Download PDF

Info

Publication number
CN101448854A
CN101448854A CNA2007800185186A CN200780018518A CN101448854A CN 101448854 A CN101448854 A CN 101448854A CN A2007800185186 A CNA2007800185186 A CN A2007800185186A CN 200780018518 A CN200780018518 A CN 200780018518A CN 101448854 A CN101448854 A CN 101448854A
Authority
CN
China
Prior art keywords
polypeptide
fusion protein
receptor
binding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800185186A
Other languages
English (en)
Chinese (zh)
Inventor
卡米洛·科拉科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of CN101448854A publication Critical patent/CN101448854A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2007800185186A 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白 Pending CN101448854A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605735.0A GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response
GB0605735.0 2006-03-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013102732781A Division CN103396495A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白

Publications (1)

Publication Number Publication Date
CN101448854A true CN101448854A (zh) 2009-06-03

Family

ID=36383953

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013102732781A Pending CN103396495A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
CNA2007800185186A Pending CN101448854A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2013102732781A Pending CN103396495A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白

Country Status (6)

Country Link
US (2) US20090186025A1 (enExample)
EP (1) EP2007807A2 (enExample)
JP (1) JP2009529906A (enExample)
CN (2) CN103396495A (enExample)
GB (1) GB0605735D0 (enExample)
WO (1) WO2007107797A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106337040A (zh) * 2016-08-28 2017-01-18 苏州普罗达生物科技有限公司 一种内皮细胞受体蛋白酪氨酸激酶a2免疫原多肽及其用途
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
CN116916950A (zh) * 2021-03-04 2023-10-20 螺旋纳米技术公司 包含Sbi佐剂的组合物及其使用方法
CN119841940A (zh) * 2025-03-19 2025-04-18 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
KR101722305B1 (ko) 2007-01-30 2017-03-31 에피백스, 인크. 조절 ｔ 세포 에피토프, 그의 조성물 및 용도
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
CN101679949B (zh) * 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
AU2010303568B2 (en) * 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
US9962436B2 (en) * 2012-07-26 2018-05-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN106366179A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种跨膜硫酸乙酰肝泰蛋白多糖1免疫激动剂多肽及其用途
CN106366180A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种上皮生长因子受体免疫原多肽及其用途
CN113412123A (zh) * 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
CN110093360B (zh) * 2019-04-15 2021-06-15 华南农业大学 一种表达Fc片段的狂犬病病毒G蛋白的融合蛋白及其制备方法
CN112870344B (zh) * 2019-11-29 2022-07-19 北京绿竹生物技术股份有限公司 一种重组水痘带状疱疹病毒疫苗
CN110872358B (zh) * 2019-12-04 2021-12-10 天康制药(苏州)有限公司 HA-Fc融合蛋白及其制备方法和疫苗
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
ATE204300T1 (de) * 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US6391589B1 (en) * 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
EP1093464A2 (en) * 1998-07-06 2001-04-25 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PT1346041E (pt) * 2000-11-27 2007-06-05 Praecis Pharm Inc Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica.
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
CN106337040A (zh) * 2016-08-28 2017-01-18 苏州普罗达生物科技有限公司 一种内皮细胞受体蛋白酪氨酸激酶a2免疫原多肽及其用途
CN116916950A (zh) * 2021-03-04 2023-10-20 螺旋纳米技术公司 包含Sbi佐剂的组合物及其使用方法
US12343392B2 (en) 2021-03-04 2025-07-01 Helix Nanotechnologies Inc Compositions including Sbi adjuvants and methods of use thereof
CN119841940A (zh) * 2025-03-19 2025-04-18 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用

Also Published As

Publication number Publication date
US20090186025A1 (en) 2009-07-23
US20120225067A1 (en) 2012-09-06
EP2007807A2 (en) 2008-12-31
GB0605735D0 (en) 2006-05-03
WO2007107797A2 (en) 2007-09-27
JP2009529906A (ja) 2009-08-27
WO2007107797A3 (en) 2007-11-08
CN103396495A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
CN101448854A (zh) 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
US20240408195A1 (en) Epstein-barr virus vaccines
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
US11905314B2 (en) Influenza virus vaccines and uses thereof
WO2011073692A1 (en) Proteins, nucleic acid molecules and compositions
US20100098719A1 (en) Fusion Proteins Comprising Two or More IgG Binding Domains of Streptococcal Protein G
CN109678937B (zh) H3n2亚型流感病毒血凝素蛋白的突变体及其应用
CN104136039A (zh) 靶向交叉呈递的树突状细胞的疫苗体
US20230355745A1 (en) Coronavirus-derived receptor-binding domain variant having reduced ace2-binding affinity and vaccine composition comprising the same
US12397050B2 (en) Universal mammalian influenza vaccine
TW201736599A (zh) 靶向豬蘭格素(langerin)之抗原
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
WO2008015480A2 (en) Composition and method for modulating an immune response
CN118176204A (zh) 截短的流感神经氨酸酶及其使用方法
JP2011502521A (ja) Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
US20240398928A1 (en) Immunogenic compositions and their use
JP7167088B2 (ja) インフルエンザウイルスワクチンおよびその使用
WO2023020637A1 (es) Antigenos quimericos para el control de coronavirus y composiciones que los comprenden

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090603

WD01 Invention patent application deemed withdrawn after publication